Jefferies lowered the firm’s price target on Equillium (EQ) to $4 from $8 and keeps a Buy rating on the shares. The company’s recent $30M financing marks a new chapter as it pivots to a new lead pipeline asset, focused initially on the large commercial opportunity in ulcerative colitis, the analyst tells investors in a research note. The firm finds the pre-clinical data generated encouraging/supporting evidence and looks forward to the first-in-human trial set to start in mid-2026. Jefferies added that it updated its revenue model for EQ504 in moderate to severe UC, leading to the new price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EQ:
- Equillium’s Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial Uncertainties
- 3 Penny Stocks to Watch Now, 8/12/25
- Equillium Stock (EQ) Rockets 140% on $50M Private Placement
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Equillium Secures $30 Million in Private Placement